Author:
Khabnadideh Soghra,solhjoo Aida,Heidari Reza,Amiri Zirtol Leila,Sakhteman Amirhossein,Rezaei Zahra,Babaei Elaheh,Rahimi Samaneh,Emami Leila
Abstract
AbstractA series of 2-aryl/alkyl-2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines (S1–S11) were synthesized with an eco-friendly and recoverable nanocatalyst (GO-Fe3O4–Ti(IV)) as an efficient magnetic composite. The new nanocatalyst was characterized by FT-IR, XRD and, EDS analysis. A conformable procedure, easy to work up and having a short reaction time with high yields are some advantages of this method. The new catalyst is also thermal-stable, reusable and, environment-friendly. The chemical structures of the synthesized 1,3-oxazine compounds were confirmed by comparing their melting points with those reported in literature. Then, the anticonvulsant activity of these compounds was assessed by the intraperitoneal pentylenetetrazole test (ipPTZ). Compounds S10 and S11 displayed considerable activity against chemically-induced seizure tests. The molecular simulation was also done to achieve their binding affinities as γ‐aminobutyric acid A (GABA‐A) receptor agonists as an assumptive mechanism of their anticonvulsant action. The result of molecular studies represented strongly matched with biological activity. Molecular docking simulation of the potent compound (S10) and diazepam as the positive control was performed and some critical residues like Thr262, Asn265, Met286, Phe289, and Val290 were identified. Based on the anticonvulsant results and also in silico ADME predictions, S11 can be to become a potential drug candidate as an anticonvulsant agent.
Funder
Shiraz University of Medical Sciences
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Somashekhar M, Kotnal R. synthesis and invivo anticonvulsant evalvation of 1-{5-[4-(morpholin-4-yl) phenyl]-1, 3, 4-oxadiazol-3 (2h)-yl} ethanone drrivatives. World J Pharm Res. 2019;8(6):316–27.
2. Thijs RD, Surges R, O’Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10172):689–701.
3. Cheke RS, Shinde SD, Ambhore JP, Chaudhari SR, Bari SB. Quinazoline: an update on current status against convulsions. J Mol Struct. 2022;1248: 131384.
4. Emami L, Moezi L, Amiri-Zirtol L, Pirsalami F, Divar M, Solhjoo A, et al. Anticonvulsant activity, molecular modeling and synthesis of spirooxindole-4H-pyran derivatives using a novel reusable organocatalyst. Mol Divers. 2022. https://doi.org/10.1007/s11030-021-10372-7.
5. Galanopoulou AS, Buckmaster PS, Staley KJ, Moshé SL, Perucca E, Engel J Jr, et al. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia. 2012;53(3):571–82.